"RNAi Therapeutics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of disease treatment which involves the silencing of genes that are associated with a disease by the process of RNA INTERFERENCE.
| Descriptor ID |
D000067492
|
| MeSH Number(s) |
E02.095.301.250
|
| Concept/Terms |
RNAi Therapeutics- RNAi Therapeutics
- RNAi-Based Therapeutics
- RNAi-Based Therapy
- RNAi Based Therapy
- RNAi-Based Therapies
- Therapies, RNAi-Based
- Therapy, RNAi-Based
- RNAi Therapy
- RNAi Therapies
- Therapies, RNAi
- Therapy, RNAi
|
Below are MeSH descriptors whose meaning is more general than "RNAi Therapeutics".
Below are MeSH descriptors whose meaning is more specific than "RNAi Therapeutics".
This graph shows the total number of publications written about "RNAi Therapeutics" by people in this website by year, and whether "RNAi Therapeutics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2021 | 1 | 0 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "RNAi Therapeutics" by people in Profiles.
-
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb; 14(2):123-136.
-
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct; 167(5):1008-1018.e5.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
-
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genet Med. 2022 03; 24(3):654-662.
-
Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy. Nano Lett. 2019 08 14; 19(8):5356-5365.
-
Gene Delivery in Lipid Research and Therapies. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):62-69.
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
-
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.
-
Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies. Circ Res. 2018 03 02; 122(5):678-692.